Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Switching Therapy Following Suboptimal Response in Chronic Myelogenous Leukemia

November 7th 2012

Now that several effective agents are FDA-approved for the treatment of CML, it is important to ascertain whether a treatment is working, and if not, how to respond in terms of switching treatment.

Current and Emerging Strategies for Managing Relapsed/Refractory Hodgkin Lymphoma

November 5th 2012

Transplant remains the cornerstone of treatment for relapsed/refractory Hodgkin lymphoma, but some new approaches are on the horizon and may also prove to be valid options.

Small-Molecule Inhibitors Hold Promise for Elderly CLL Patients

October 29th 2012

In early clinical trials, small-molecule inhibitors have demonstrated improvement in response rates in elderly patients with chronic lymphocytic leukemia.

FDA Approves Synribo for CML

October 26th 2012

The FDA has approved omacetaxine mepesuccinate for the treatment of adult patients with Philadelphia chromosome-positive CML who have progressed after treatment with at least two prior TKIs.

Detecting Bone Disease in Multiple Myeloma Patients

October 16th 2012

It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.

First-Line Dose-Dense Induction and High-Dose Chemotherapy/Autologous Stem Cell Transplant Benefits Patients With Rare Lymphomas

October 8th 2012

Dose-dense induction with high-dose chemotherapy/autologous stem-cell transplantation is reasonable for use as first-line treatment of transplantation-eligible patients with systemic peripheral T-cell lymphomas.

Lessons on Patient Care Learned at Home

September 28th 2012

This fellow shares the insights heâ€™s gained from his wife, a pediatric oncology nurse, and how they help in the care he provides.

Decitabine Outperforms Standard Treatments in Older Patients With Acute Myeloid Leukemia

September 27th 2012

Decitabine produced a higher response rate than standard therapies in older patients with newly diagnosed acute myeloid leukemia without major differences in safety.

Dr. Zelenetz Previews the 2012 ASH Annual Meeting

September 26th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.

Beyond Tumor Type: HER2 Link in Leukemia Setting Shows Molecular Profiling Potential

September 21st 2012

Trastuzumab has demonstrated activity in patients with B-cell adult acute lymphocytic leukemia who exhibit evidence of upregulation of the HER2 receptor.

On the Horizon for Multiple Myeloma: Update on Novel Agents, Bone Therapies

September 12th 2012

A new generation of proteasome inhibitors, immunomodulatory agents, and deacetylase inhibitors are currently being investigated in clinical trials to treat patients with relapsed or refractory multiple myeloma.

Bosutinib Approved for Previously Treated CML

September 4th 2012

The FDA has approved bosutinib for the treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia who are intolerant or who have become resistant to prior therapy.

Lenalidomide Maintenance After Stem-Cell Transplantation Benefits Patients With Multiple Myeloma

August 31st 2012

Lenalidomide used continuously after autologous hematopoietic stem cell transplantation significantly prolonged the time to disease progression and overall survival in patients with multiple myeloma.

FDA Approves Marqibo for Rare Form of Leukemia

August 9th 2012

The FDA approved Marqibo to treat patients with Philadelphia chromosome-negative adult acute lymphoblastic leukemia following at least two relapses or failed treatment.

Ponatinib Achieves Primary Endpoints in CML Subtypes

August 8th 2012

Ponatinib, an oral multikinase inhibitor, generated significant responses in more than 50% of patients with certain chronic myeloid leukemia subtypes.

Carfilzomib Shows Promise as Alternative to Bortezomib in Multiple Myeloma

August 2nd 2012

Two separate clinical trials presented at ASCO 2012 suggest that carfilzomib would be a safe and effective alternative to bortezomib for the treatment of multiple myeloma, following progression.

Dr. Rummel on the Chemical Structure of Bendamustine

July 30th 2012

Dr. Mathias Rummel, from the University Hospital Giessen in Germany, on the Bendamustine Chemical Structure

Researchers Share Honor for Bortezomib Discovery

July 27th 2012

Bortezomib represented a major discovery in cancer research and has helped some patients achieve a complete pathological response and live longer.

FDA Approves Carfilzomib for Relapsed Multiple Myeloma

July 23rd 2012

The FDA approved carfilzomib for patients with multiple myeloma who have received at least two prior lines of therapy.

Antibody-Drug Conjugates: Guided Missiles Deployed Against Cancerous Cells

July 5th 2012

Antibodies directed against tumor cell antigens or overexpressed proteins are currently the fastest-growing class of targeted cancer therapeutics.